Bruker (NASDAQ:BRKR) Issues FY 2025 Earnings Guidance

Key Points

• Bruker has issued its FY 2025 earnings guidance, projecting an EPS of 1.950-2.050 and revenue between $3.4 billion to $3.5 billion, which is lower than the consensus estimates.
• The company's stock price decreased by 1.1% and has a market capitalization of approximately $5.76 billion.
• Recent analyst ratings indicate a shift, with Goldman Sachs and UBS lowering their target prices to $45.00, reflecting a "neutral" outlook on the stock.

Bruker (NASDAQ:BRKR - Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided EPS guidance of 1.950-2.050 for the period, compared to the consensus EPS estimate of 2.445. The company issued revenue guidance of $3.4 billion-$3.5 billion, compared to the consensus revenue estimate of $3.5 billion.

Bruker Stock Down 1.1%

Bruker stock opened at $37.99 on Monday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.74 and a current ratio of 1.57. The firm has a market capitalization of $5.76 billion, a price-to-earnings ratio of 73.06, a price-to-earnings-growth ratio of 2.56 and a beta of 1.16. Bruker has a fifty-two week low of $34.10 and a fifty-two week high of $72.94. The stock's fifty day moving average is $39.94 and its two-hundred day moving average is $43.35.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.11). Bruker had a net margin of 2.31% and a return on equity of 19.47%. Analysts predict that Bruker will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Monday, June 16th were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 16th. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker's dividend payout ratio is 38.46%.

Analyst Ratings Changes

BRKR has been the topic of several research reports. The Goldman Sachs Group lowered their target price on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. UBS Group lowered their target price on Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Citigroup lowered Bruker from a "strong-buy" rating to a "hold" rating and lowered their target price for the company from $50.00 to $40.00 in a report on Thursday, May 22nd. Wells Fargo & Company decreased their price objective on Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. Finally, Barclays decreased their price objective on Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $52.89.

Insider Activity at Bruker

In other Bruker news, CEO Frank H. Laukien purchased 2,608 shares of the firm's stock in a transaction on Friday, June 6th. The shares were purchased at an average cost of $38.36 per share, with a total value of $100,042.88. Following the purchase, the chief executive officer owned 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. This represents a 0.01% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 27.30% of the stock is currently owned by insiders.

Institutional Trading of Bruker

A number of hedge funds have recently added to or reduced their stakes in BRKR. Jacobs Levy Equity Management Inc. acquired a new stake in Bruker in the 1st quarter worth about $262,000. Focus Partners Wealth boosted its stake in Bruker by 115.0% in the 1st quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company's stock worth $469,000 after buying an additional 6,008 shares during the last quarter. Royal Bank of Canada boosted its stake in Bruker by 8.3% in the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company's stock worth $5,148,000 after buying an additional 9,501 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Bruker by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company's stock worth $15,285,000 after buying an additional 9,235 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Bruker by 107.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company's stock worth $61,162,000 after buying an additional 758,301 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.